Holen Sie sich die Stockscreener-App
40.91
0.89%
0.50
Schlusskurs vom Vortag:
$40.41
Offen:
$40.92
24-Stunden-Volumen:
169.42K
Relative Volume:
0.23
Marktkapitalisierung:
$3.20B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-170.19M
KGV:
-13.42
EPS:
-3.0495
Netto-Cashflow:
$-154.68M
1W Leistung:
+1.54%
1M Leistung:
+11.30%
6M Leistung:
+160.50%
1J Leistung:
+126.12%
1-Tages-Spanne:
$40.50
$42.40
1-Wochen-Bereich:
$39.20
$42.93
52-Wochen-Spanne:
$10.91
$45.76
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
40.74 | 3.17B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.30 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.20 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.27 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Market Review: Is RBNE stock risky to hold now2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
DLD Asset Management LP Acquires New Position in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Globe and Mail
Weekly Earnings: What is the implied volatility of Spyre Therapeutics IncMarket Activity Recap & Community Driven Trade Alerts - baoquankhu1.vn
Patterns Watch: Can Spyre Therapeutics Inc grow without external fundingMarket Trend Review & Technical Confirmation Trade Alerts - baoquankhu1.vn
Trading Recap: Can Spyre Therapeutics Inc deliver consistent EPS growthVolume Spike & Weekly Top Performers Watchlists - baoquankhu1.vn
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - AOL.com
Assessing Spyre Therapeutics (SYRE) Valuation After A Year Of Strong Shareholder Returns - Yahoo Finance
Insider Selling: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE) - GuruFocus
Scott Burrows Sells 2,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $632,850.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
Investment Review: Is Spyre Therapeutics Inc a top pick in the sectorPortfolio Return Report & Verified Entry Point Signals - baoquankhu1.vn
Spyre Therapeutics CEO Sells 15,000 Shares - TradingView
Support Test: Can Spyre Therapeutics Inc lead its sector in growthPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Aug Analyst Calls: Can Spyre Therapeutics Inc lead its sector in growth - baoquankhu1.vn
Insider Selling: Cameron Turtle Sells 15,000 Shares of Spyre The - GuruFocus
Morgan Stanley broker lists 60,000-share SYRE resale (SYRE) - Stock Titan
SYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[EFFECT] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
SYRE PE Ratio & Valuation, Is SYRE Overvalued - Intellectia AI
Spyre Therapeutics, Inc. (SYRE): Investor Outlook Amid A 35% Potential Upside - DirectorsTalk Interviews
[POS AM] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. targets breakthrough in inflammatory bowel disease with combination therapies - Traders Union
Spyre reports enhanced efficacy of anti-TL1A and anti-IL-23 combination - BioWorld MedTech
Assessing Spyre Therapeutics (SYRE) Valuation After A Powerful Multi‑Period Share Price Run - simplywall.st
Insider Sell: Can Spyre Therapeutics Inc maintain sales growthTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Spyre Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Bull Bear: Is Spyre Therapeutics Inc a top pick in the sector2025 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
SYRESpyre Therapeutics Latest Stock News & Market Updates - Stock Titan
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Deutsche Bank Adjusts Spyre Therapeutics PT to $55 From $45, Maintains Buy Rating - marketscreener.com
Spyre Therapeutics stock dips premarket after Friday surge as $500 million shelf hangs over shares - TechStock²
Wells Fargo & Company Forecasts Strong Price Appreciation for Spyre Therapeutics (NASDAQ:SYRE) Stock - Defense World
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Spyre Therapeutics (SYRE) and Tandem Diabetes Care (TNDM) - The Globe and Mail
Gains Report: Can Spyre Therapeutics Inc. (3920) stock surprise markets with earningsMarket Sentiment Summary & Free Fast Entry Momentum Trade Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Organigram Global (OGI) and Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre Therapeutics (NASDAQ:SYRE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Spyre Therapeutics stock hits 52-week high at 42.93 USD - Investing.com India
Spyre Therapeutics (SYRE) Buy Rating Reiterated by BTIG | SYRE S - GuruFocus
Spyre Therapeutics stock hits 52-week high at 42.93 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics Stocks Surge Amid Cash Flow and Research Developments - timothysykes.com
How buybacks impact Spyre Therapeutics Inc. stock valueInflation Watch & Weekly Watchlist for Hot Stocks - mfd.ru
Spyre Therapeutics Surprises with Strong Q4 Despite Losses - StocksToTrade
Wells Fargo Raises Price Target for Spyre Therapeutics (SYRE) to $50 | SYRE Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price - MarketBeat
Spyre Therapeutics Stock Jumps on Pipeline Momentum - TipRanks
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3%Time to Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Receives Buy Rating from BTIG Research - MarketBeat
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):